CAMP4 THERAPEUTICS CORPORATION

CAMP4 Therapeutics announced the closing of the second tranche of its previously announced private placement, receiving approximately $50.1 million in gross proceeds. The second closing involved the sale of 10,756,498 shares of common stock at $1.53 per share, 39,306 shares at $1.65 to certain directors, employees and consultants, and 21,925,368 pre-funded warrants at $1.5299 each. Investors in this tranche included Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners and CURE SYNGAP1. The company intends to use the net proceeds to advance CMP-002, its lead investigational antisense oligonucleotide therapeutic candidate for SYNGAP1-related disorder, which recently received clearance in Australia to begin a Phase 1/2 clinical trial, and to support its early-stage pipeline. Leerink Partners acted as lead placement agent, with Piper Sandler & Co., Cantor Fitzgerald & Co. and Wedbush Securities Inc. as co-placement agents.

Universe Pharmaceuticals led Monday's biotech gainers with shares soaring nearly 100% after its SEC filing showed a narrowed net loss for the six months ended March 31, 2026. Revenue was $9.03 million and net loss was $1.55 million, or $2.76 per share, compared with a net loss of $3.28 million, or $9.44 per share, in the year-ago period. Cumberland Pharmaceuticals jumped over 38% ahead of its second-quarter 2026 results due Tuesday, following last month's sale of its branded portfolio to an Apotex Health unit for $100 million in cash. Autolus Therapeutics gained over 22% after reporting preliminary second-quarter AUCATZYL net product revenue of approximately $45 million, up 70% sequentially and more than 100% year over year. Other notable movers included Pulmonx, up over 30% after reaffirming full-year 2026 revenue guidance of $90 million to $92 million, and CAMP4 Therapeutics, which rose over 22% after receiving Australian clearance to begin a Phase 1/2 trial of CMP-002, satisfying a condition to raise up to $50 million in a private placement.

JPMorgan upgraded CAMP4 Therapeutics to Overweight from Neutral and raised its price target to $9 from $5, citing the potential of its CMP-002 candidate for SYNGAP1-related disorder. The firm noted that CAMP4 has completed GLP toxicology studies for CMP-002 and received regulatory guidance from multiple jurisdictions, supporting program advancement. Earlier in May, the company reported that CMP-002 treatment led to statistically significant improvements in seizure resistance and reduced seizure severity in SYNGAP1 haploinsufficient mice. CAMP4 plans to move CMP-002 into a Phase 1/2 clinical trial in the second half of 2026.